Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.To expand its portfolio of novel biopharmaceutical products
Subscribe to our email newsletter
HUYA Bioscience International has entered into a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH).
The agreement with GIBH is expected to provide HUYA the right of first review and negotiation for the licensing and development of certain novel compounds owned or controlled by GIBH.
Dr Mireille Gingras, CEO of HUYA, said: “HUYA continues to be on the forefront of creating partnerships with leading Chinese institutions such as GIBH that will lead to the accelerated development of novel therapeutics. GIBH is an important pharmaceutical R&D institute in South China, and we are excited to partner with this regional leader to identify and pursue novel product opportunities.”
Earlier, HUYA has entered into strategic partnerships with institutions, including Shenyang Pharmaceutical University and the Beijing Institute of Material Medica, to expand its portfolio of novel biopharmaceutical products.